AMGN - Amgen Inc.
| Previous close | 171.56 |
| Open | 171.62 |
| Bid | 172.95 x 100 |
| Ask | 178.80 x 100 |
| Day's range | 171.26 - 176.97 |
| 52-week range | 152.16 - 201.23 |
| Volume | 3,568,697 |
| Avg. volume | 5,253,753 |
| Market cap | 116.72B |
| Beta | 1.71 |
| PE ratio (TTM) | 64.93 |
| EPS (TTM) | 2.69 |
| Earnings date | 24 Apr 2018 |
| Forward dividend & yield | 5.28 (3.08%) |
| Ex-dividend date | 2018-05-16 |
| 1y target est | 195.14 |
- Motley Fool•57 minutes ago
Better Buy: Amgen Inc. vs. Celgene
How these two big biotechs compare in three key areas.
- CNBC•12 hours ago
Stocks could see more turbulence as 10-year yield inches to important 3 percent level
Rising interest rates are likely to sting the stock market, but a 3 percent or even higher 10-year yield isn't enough to cause a meltdown.
- Zacks•19 hours ago
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
- Zacks•19 hours ago
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
- CNBC•3 days ago
Interest-rate worries may not be offset by good earnings news in the week ahead
Rising interest rates and inflation worries could hang over the stock market in the coming week, as investors look to a big flood of earnings news to lift some of their anxiety.
- Zacks•4 days ago
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
- Motley Fool•4 days ago
3 Stocks You Can Safely Own Until 2030
If you're looking for stocks built to last, check out Amgen, Berkshire Hathaway, and Aptiv.
Market Realist•5 days agoGilead Sciences Expects Decline in Earnings in Fiscal 2018
Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.
Market Realist•6 days agoGilead Sciences May Witness Significant Drop in Revenues in 2018
Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...
Market Realist•6 days agoWhat Analysts Recommend for Gilead Sciences in April 2018
In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.
- Zacks•6 days ago
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
- Business Insider UK•7 days ago
Amgen's Aimovig halved migraine days in 30 percent of trial patients
A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday. The 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.
- Business Insider UK•7 days ago
Amgen's Aimovig halved migraine days in 30 percent of trial patients
A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday. The 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.
- Market Realist•7 days ago
Risankizumab Could Be AbbVie’s Long-Term Growth Driver
In December 2017, AbbVie (ABBV) announced positive top-line results for its pivotal Phase 3 IMMhance trial to evaluate the safety and efficacy of risankizumab 150 mg1 for the treatment of individuals with moderate-to-severe plaque psoriasis.
- Market Realist•8 days ago
How AbbVie’s Humira Performed in 4Q17 and 2017
AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.
Market Realist•8 days agoHow AbbVie Performed in 4Q17 and Fiscal 2017
AbbVie (ABBV) generated revenue of $7.7 billion in 4Q17 and $6.8 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~11% growth quarter-over-quarter. AbbVie reported revenue of $28.2 billion in fiscal 2017 and $25.6 billion in fiscal 2016, representing ~10% YoY growth.
- Market Realist•8 days ago
Analysts’ Recommendations for Johnson & Johnson on April 16
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
- Market Realist•12 days ago
Exploring the Growth Trajectory of Amgen’s Repatha
Amgen (AMGN) is one of the world’s leading biotechnology companies, with a presence in ~100 countries. Amgen’s Repatha is a human monoclonal antibody that inhibits proprotein convertase kexin type nine (or PCSK9). The drug has been approved in more than 50 regions, including the United States, Japan, Canada, and the European Union.
- Market Realist•13 days ago
Incyte Expected to Report Robust Revenue Growth in Fiscal 2018
In 2017, Incyte (INCY) reported total revenues of close to $1.5 billion, which was year-over-year (or YoY) growth of around 38.9%. The company earned revenues close to $1.1 billion from the sale of Jakafi, a JAK1/JAK2 inhibitor, in the US, and $152 million as royalties received from Novartis (NVS) on the sale of Jakafi, marketed as Jakavi, in international markets. Wall Street analysts have projected Incyte’s fiscal 2018 revenues to be close to $1.8 billion, which is a YoY rise of around 16.9%.
Market Realist•13 days agoWhat Analysts Recommend for Incyte in April 2018
On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.
- Market Realist•14 days ago
Amgen Stock Performance in 1Q18
Amgen (AMGN) is a biotechnology company with headquarters in Thousand Oaks, California. Amgen discovers, develops, and delivers drugs for various therapeutic areas, including cardiovascular, neuroscience, and oncology.
- Business Insider UK•14 days ago
Rhode Island governor says Amgen will build another plant in state
The plant will use Amgen's new flexible and reconfigurable technology, part of the company's ongoing efforts to control costs. Amgen, headquartered in Thousand Oaks, California, said in January it would locate the new plant in the United States, due in part to a lower effective tax rate stemming from U.S. tax reform. The company will also receive corporate tax incentives linked to job creation from Rhode Island, according to Governor Gina Raimondo.
- Business Insider UK•14 days ago
Rhode Island governor says Amgen will build another plant in state
The plant will use Amgen's new flexible and reconfigurable technology, part of the company's ongoing efforts to control costs. Amgen, headquartered in Thousand Oaks, California, said in January it would locate the new plant in the United States, due in part to a lower effective tax rate stemming from U.S. tax reform. The company will also receive corporate tax incentives linked to job creation from Rhode Island, according to Governor Gina Raimondo.
- Investor's Business Daily•19 days ago
AbbVie Deal Allows Biogen To Launch Humira Copy In Europe
AbbVie put another brick in the wall surrounding key moneymaker Humira early Thursday, announcing a deal that prevents Biogen from launching a copycat in the U.S. until June 2023.
Business Wire•19 days agoThe World’s Best Cyclists Are Coming to California for America’s Only WorldTour Race as the Amgen Tour of California Gets Ready to Roll in May
LOS ANGELES--(BUSINESSWIRE)-- Men and Women World Champions, Olympic Medalists and Tour de France Veterans Set to Compete in America’s Biggest Race Join the Celebration with a Flyaway Sweepstakes to Meet ...
